MEEGAN CHESTNUT: Open Payments
NPI 1255513636 · COLUMBIA, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$462 in 21 payments from 8 companies in 2025. Trend: 2023 $488 · 2024 $789 · 2025 $462
Food & beverage: $462
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 11 | $233 |
| Lilly USA, LLC | 3 | $68 |
| AstraZeneca Pharmaceuticals LP | 2 | $47 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $30 |
| Hologic Sales and Service, LLC | 1 | $29 |
| Esperion Therapeutics, Inc. | 1 | $22 |
| Currax Pharmaceuticals LLC | 1 | $17 |
| Abbott Laboratories | 1 | $15 |
Products named: Ozempic, Rybelsus, Wegovy, MOUNJARO, AIRSUPRA, Kerendia, APTIMA, NEXLETOL.
Industry payments across MD — which companies pay providers there.
